Prof. Åke Sjöholm

Karolinska Institute, Sweden

Email: [email protected]

Qualifications

1991 Ph.D., Uppsala University, Sweden

1988 M.D., Uppsala University, Sweden

1984 M.B., Uppsala University, Sweden

Publications(Selected)

1. Zhao, T., Cen, J., Wang, X., et al. (2026). The Welander TIA1 mutation dedifferentiates insulin-producing cells: Reversal by a GLP-1 receptor agonist. Journal of Biological Chemistry, 302(4), 111336.
2. Sjöholm, Å., & Rao, A. D. (2026). Editorial: World diabetes day 2024: Exploring mechanisms, innovations, and holistic approaches in diabetes care. Frontiers in Endocrinology, 17, 1808396.
3. Sjöholm, Å., Bennet, L., & Nilsson, P. M. (2025). Cognitive dysfunction in diabetes - the 'forgotten' diabetes complication: A narrative review. Scandinavian Journal of Primary Health Care, 43(2), 448–454.
4. Sjöholm, Å., & Mahma, H. (2024). Glycogenic hepatopathy. New England Journal of Medicine, 391(16), 1528.
5. Sjöholm, Å. (2024). Glucokinase activators and imeglimin: New weaponry in the armamentarium against type 2 diabetes. BMJ Open Diabetes Research & Care, 12(4), e004291.
6. Grigoriadis, G., Koufakis, T., Kotsa, K., et al. (2023). Epidemiological, pathophysiological, and clinical considerations on the interplay between thyroid disorders and type 2 diabetes mellitus. Medicina, 59(11), 2013.
7. Zhao, T., Wang, X., Cen, J., et al. (2023). The Welander distal myopathy TIA1 mutation promotes a proinsulin to insulin processing defect in human insulin producing EndoC-betaH1 cells. Diabetologia, 66(Suppl 1), S207–S208.
8. Siraj, E. S., Sjöholm, Å., & Sumner, A. E. (2023). Diabetes in Africa in the 21st century: The unique and important challenge of diabetes in Africa, volume II. Frontiers in Public Health, 11, 1265439.
9. Zhao, T., Wang, X., Cen, J., et al. (2023). The Welander distal myopathy TIA1 mutation promotes partial beta cell to alpha cell transdifferentiation in human EndoC-betaH1 cells. Diabetic Medicine, 40(Suppl 1), P14.
10. Sjöholm, Å., Corbett, J. A., Leung, P. S., et al. (2022). Editorial: Understanding the gene expression of β cell dysfunction in diabetes. Frontiers in Endocrinology, 13, 1069991.
11. Sjöholm, Å. (2021). Using adjuvant pharmacotherapy in the treatment of type 1 diabetes. Expert Opinion on Pharmacotherapy, 22(16), 2143–2148.
12. Sjöholm, Å. (2020). Atypical diabetes: A diagnostic challenge. BMJ Open Diabetes Research & Care, 8(1), e001470.
13. Sjöholm, Å. (2019). Ketosis-prone type 2 diabetes: A case series. Frontiers in Endocrinology, 10, 684.
14. Darsalia, V., Nathanson, D., Nyström, T., et al. (2014). GLP-1R activation for the treatment of stroke: Updating and future perspectives. Reviews in Endocrine and Metabolic Disorders, 15(3), 233–242.
15. Darsalia, V., Hua, S., Larsson, M., et al. (2014). Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLOS ONE, 9(8), e103114.
16. Fransson, L., Sjöholm, Å., & Ortsäter, H. (2014). Inhibition of palmitate-induced GADD34 expression augments apoptosis in mouse insulinoma cells (MIN6). Cell Biochemistry and Function, 32(5), 445–452.
17. Kappe, C., Zhang, Q. M., Nyström, T., et al. (2014). Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. Diabetology & Metabolic Syndrome, 6, 70.
18. Ortsäter, H., Grankvist, N., Honkanen, R. E., et al. (2014). Protein phosphatases in pancreatic islets. Journal of Endocrinology, 221(3), R121–R144.
19. Darsalia, V., Olverling, A., Larsson, M., et al. (2014). Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regulatory Peptides, 190, 25–31.
20. Eriksson, L., Saxelin, R., Rohl, S., et al. (2014). Effects of the glucagon-like peptide-1 analog Exendin-4 on reendothelialization and intimal hyperplasia formation in an animal model of vascular injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(Suppl 1), A515.

Profile Details
https://scholar.google.com/citations?user=r2X6jkMAAAAJ&hl=sv
https://www.researchgate.net/scientific-contributions/A-Sjoeholm-38289014
https://www.mededmeetings.com/conferences/speakerdetails/3/53

WOS ResearcherID: DZU-4195-2022